Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response

Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft-tissue sarcomas refractory to standard therapies. Inactivation of NF1 and subsequent upregulation of RAS/RAF/MEK/ERK signaling exist in the majority of MPNSTs. However, the lack of preclinical assessment of MEK inhibitors in MPNSTs hind...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yihui, Wang, Wei, Li, Yuehua, Li, Haibo, Guo, Zizhen, Wei, Chengjiang, Long, Manmei, Chung, Manhon, Aimaier, Rehanguli, Li, Qingfeng, Wang, Zhichao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303010/
https://www.ncbi.nlm.nih.gov/pubmed/35875109
http://dx.doi.org/10.3389/fonc.2022.903177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303010/
https://www.ncbi.nlm.nih.gov/pubmed/35875109
http://dx.doi.org/10.3389/fonc.2022.903177

Ejemplares similares